Oral Contraceptive Pill Pretreatment in Polycystic Ovary Syndrome Patients Undergoing IVF/ICSI Using the Gonadotrophin Releasing Hormone Antagonist Protocol (A Randomized Controlled Trial)

700 women with PCOS undergoing IVF/ICSI using flexible GnRH antagonist protocol, were included in the study, and randomized to either OCP pretreatment (n = 350), or no pretreatment (n = 350). The latter group received OCP pretreatment in the form of 30µg ethinyl estradiol / 3mg drospirenone (Yasmin®...

Full description

Saved in:
Bibliographic Details
Published in:QJM : An International Journal of Medicine 2023-08, Vol.116 (Supplement_1)
Main Authors: Tamara, Tarek Fathy, El-Saed Abou Gamrah, Amgad, Gomaa, Mostafa Fouad, Abbas, Ahmed Mohamed, El-Sawy, Khaled Afifi
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:700 women with PCOS undergoing IVF/ICSI using flexible GnRH antagonist protocol, were included in the study, and randomized to either OCP pretreatment (n = 350), or no pretreatment (n = 350). The latter group received OCP pretreatment in the form of 30µg ethinyl estradiol / 3mg drospirenone (Yasmin®, Bayer AG, Berlin, Germany) pills for an interval of 21 to 28 days; after which COH was started following a 5-day pill wash-out period. OCP-pretreated PCOS women had more retrieved oocytes, albeit, on the expense of increased gonadotropin consumption. However, this increased oocyte yield did not translate to a significant effect on conception rates among intended-to-treat PCOS woman receiving OCP pretreatment. Conversely, it shifted among OCP-pretreated women who actually started COH cycle, to a significant 18% reduction in the probability of successful pregnancy.
ISSN:1460-2725
1460-2393
DOI:10.1093/qjmed/hcad069.551